Analysis and Commentary STEVEN GROSSMAN 12/16/22 Analysis and Commentary STEVEN GROSSMAN 12/16/22 FDA Benefits If You Join the Alliance for a Stronger FDA Read More Analysis and Commentary STEVEN GROSSMAN 12/9/22 Analysis and Commentary STEVEN GROSSMAN 12/9/22 Webinar with Valerie Jensen, Associate Director of FDA’s Drug Shortage Staff Read More Analysis and Commentary STEVEN GROSSMAN 12/2/22 Analysis and Commentary STEVEN GROSSMAN 12/2/22 FDA and Continuing Resolutions: Everything You Need to Know Read More Analysis and Commentary STEVEN GROSSMAN 11/18/22 Analysis and Commentary STEVEN GROSSMAN 11/18/22 The F in FDA: Part 3 Read More Analysis and Commentary STEVEN GROSSMAN 11/11/22 Analysis and Commentary STEVEN GROSSMAN 11/11/22 The F in FDA: Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 11/4/22 Analysis and Commentary STEVEN GROSSMAN 11/4/22 The F in FDA: Both Funding and Reforms Needed to Improve Food Programs Read More Analysis and Commentary STEVEN GROSSMAN 10/28/22 Analysis and Commentary STEVEN GROSSMAN 10/28/22 Alliance Webinar with Dr. Suzanne Schwartz on Cyber Security and Digital Health Read More Analysis and Commentary STEVEN GROSSMAN 10/14/22 Analysis and Commentary STEVEN GROSSMAN 10/14/22 All About 3D Printing: An Example of FDA’s Growing Responsibilities Read More Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 12/16/22 Analysis and Commentary STEVEN GROSSMAN 12/16/22 FDA Benefits If You Join the Alliance for a Stronger FDA Read More
Analysis and Commentary STEVEN GROSSMAN 12/9/22 Analysis and Commentary STEVEN GROSSMAN 12/9/22 Webinar with Valerie Jensen, Associate Director of FDA’s Drug Shortage Staff Read More
Analysis and Commentary STEVEN GROSSMAN 12/2/22 Analysis and Commentary STEVEN GROSSMAN 12/2/22 FDA and Continuing Resolutions: Everything You Need to Know Read More
Analysis and Commentary STEVEN GROSSMAN 11/18/22 Analysis and Commentary STEVEN GROSSMAN 11/18/22 The F in FDA: Part 3 Read More
Analysis and Commentary STEVEN GROSSMAN 11/11/22 Analysis and Commentary STEVEN GROSSMAN 11/11/22 The F in FDA: Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 11/4/22 Analysis and Commentary STEVEN GROSSMAN 11/4/22 The F in FDA: Both Funding and Reforms Needed to Improve Food Programs Read More
Analysis and Commentary STEVEN GROSSMAN 10/28/22 Analysis and Commentary STEVEN GROSSMAN 10/28/22 Alliance Webinar with Dr. Suzanne Schwartz on Cyber Security and Digital Health Read More
Analysis and Commentary STEVEN GROSSMAN 10/14/22 Analysis and Commentary STEVEN GROSSMAN 10/14/22 All About 3D Printing: An Example of FDA’s Growing Responsibilities Read More
Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More
Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More
Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More
Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More
Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More
Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More
Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More
Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More
Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More
Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More
